Gazing into a crystal ball-cancer therapy in the post-genomic era

Nature Medicine

Volumn 7, Issue 3, 2001, Pages 283-285

  Ratain, Mark J ^a,b   Relling, Mary V ^b,c  

^a UNIVERSITY OF CHICAGO   (United States)

^b Pharmacogenetics of Anticancer Agents Research Group   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER; CANCER RESEARCH; CANCER RISK; CANCER THERAPY; CARCINOGENESIS; DATA ANALYSIS; DATA BASE; GENE DUPLICATION; GENE LOCATION; GENE SEQUENCE; GENOTYPE; HUMAN; MEDICAL TECHNOLOGY; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SEQUENCE ANALYSIS; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; GENOTYPE; HUMAN GENOME PROJECT; HUMANS; MICE; NEOPLASMS; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 0035105588     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/85414     Document Type: Short Survey

References (12)

1. Initial sequencing and analysis of the human genome
2. The five rules of prognostication
3. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms
4. Comparison of human genetic and sequence-based physical maps
5. Shattuck lecture - Medical and societal consequences of the human genome project
6. Cancer risk and low-penetrance susceptibility genes in gene-environment interactions
7. Pharmacogenomics: Translating functional genomics into rational therapeutics
8. Integration of cytogenetic landmarks into the draft sequence of the human genome
9. Cancer and genomics
10. A new consistent chromosomal abnormality in chronic myelogenous leukemia
11. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
12. The purine path to chemotherapy